Abstract: The present disclosure provides methods and compositions for treating glomerular hyperfiltration, reducing glycogen storage in tissues, or reducing uremic toxins in an animal, comprising orally administering a composition comprising medium chain triglycerides, eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), arginine, antioxidants, and B vitamins to the animal.

Abstract: Compositions and methods directed to a synergistic blend of amino acids for providing a health benefit to an animal are disclosed herein.

Abstract: A composition effective for restoring mitochondrial and other cellular function and/or increasing mitochondrial energy in one or more cells contains adenosylcobalamin. Other aspects are directed to method of improving in a physiological state linked to metabolic fatigue in one or more cells and/or reducing fatigue in an individual; method of treating, reducing an incidence of, and/or reducing a severity of a chronic illness and/or of a mitochondria-related disease or condition associated with altered mitochondrial function or a reduced mitochondrial density.

Abstract: The present invention relates to novel depside dimeric compounds for improving skeletal muscle plasticity regeneration to maintain or increase muscle function and/or muscle mass by modulating muscle stem cells. For example, the present invention is useful for subjects to promote muscle repair and/or subjects suffering from precachexia, cachexia, sarcopenia, myopathy, dystrophy and/or recovery after muscle injury or surgery.

Abstract: The present invention relates to novel depside trimeric compounds for improving skeletal muscle plasticity regeneration to maintain or increase muscle function and/or muscle mass by modulating muscle stem cells. For example, the present invention is useful for subjects to promote muscle repair and/or subjects suffering from precachexia, cachexia, sarcopenia, myopathy, dystrophy and/or recovery after muscle injury or surgery.

Abstract: The present invention relates to novel polymethoxyflavone compounds for improving skeletal muscle plasticity regeneration to maintain or increase muscle function and/or muscle mass by modulating muscle stem cells. For example, the present invention is useful for subjects to promote muscle repair and/or subjects suffering from precachexia, cachexia, sarcopenia, myopathy, dystrophy and/or recovery after muscle injury or surgery.

Abstract: The present invention relates to novel Raf-1 kinase inhibitor compounds for improving skeletal muscle regeneration to maintain or increase muscle function and/or muscle mass by modulating muscle stem cells. For example, the present invention is useful for subjects to promote muscle repair and/or subjects suffering from precachexia, cachexia, sarcopenia, myopathy, dystrophy and/or recovery after muscle injury or surgery.

Abstract: The present invention relates to novel SRC inhibitor compounds for improving skeletal muscle regeneration to maintain or increase muscle function and/or muscle mass by modulating muscle stem cells. For example, the present invention is useful for subjects to promote muscle repair and/or subjects suffering from precachexia, cachexia, sarcopenia, myopathy, dystrophy and/or recovery after muscle injury or surgery.